Characteristics of Regulatory T cells

  • Magdalena Frydrychowicz Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
  • Maciej Boruczkowski Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
  • Agata Kolecka-Bednarczyk Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
  • Renata Jenek Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
  • Joanna Rosołowska Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
  • Agnieszka Pluto-Prądzyńska Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
  • Grzegorz Dworacki Chair and Department of Clinical Immunology, Poznan University of Medical Sciences, Poland
Keywords: Tregs, regulatory T cells, autoimmunity, cancer


Regulatory T cells (Tregs) is heterogenic subpopulation of T cells that is able to suppress function of effector cells during the immune response. Among them are natural (nTreg) and induced Treg (Tr1, Th3, CD4+CD25-). CD25, CD45Ro, CD152, GITR, LAG-3, several adhesion molecules, chemokine receptors as well as Toll-like receptors are present on the surface of Treg. Mechanism of suppression used by nTreg is not completely understood.


Koczorowski M, Jutel M. Human T Regulatory Cells: On the Way to Cognition. Arch. Immunol. Ther. Exp. 2013; 61:229–236

Gershon RK, Konodo K. Cell interaction in the induction of tolerance: the role of thymic lymphocytes. Immunology. 1970; 18: 723–737

Ruhnau J, Schulze J, von Sarnowski B, Heinrich M, Langner S, Pötschke, Wilden A, Kessler Ch, Bröker BM, Vogelgesang A, Dressel A. Reduced Numbers and Impaired Function of Regulatory T cells in Peripheral Blood of Ischemic Stroke Patients. Mediators of Inflammation. 2016; 2016, Article ID 2974605, 9 pages.

Miyara M, Sakaguchi S. Human FoxP3+ CD4+ regulatory T cells: their knows and unknows. Immunology and Cell Biology. 2011; vol.89, no. 3, pp. 346–351.

Antony PA, Restifo NP. CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2. J Immunother. 2005; 28(2): 120–128.

Whiteside T L. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012; 22(4): 327–334.

Zoltán Fehérvári Z, Sakaguchi S. A paragon of self-tolerance: CD25+CD4+ regulatory T cells and the control of immune responses. Arthritis Res Ther. 2004; 6:19–25.

Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic selftolerance. J Immunol. 1999; 162:5317–5326.

McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC: CD4+CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002; 16:311–323.

Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG: B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol. 2001, 2:1126–1132.

Wing K, Suri-Payery E, Rudin A. CD4+CD25+-Regulatory T Cells from Mouse to Man. Scandinavian Journal of Immunology. 2005;62:1–15.

Whiteside TL. Induced regulatory T cells in inhibitory microenvironments created by cancer. Expert Opin Biol Ther. 2014 October; 14(10): 1411–1425.

Takahashi T, Kuniyasu Y, Toda M et al. Immunologic selftolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1998;10:1969–80.

Mercer F, Unutmaz D. The Biology of FoxP3: A Key Player in Immune Suppression during Infections, Autoimmune Diseases and Cancer. Adv Exp Med Biol. 2009; 665: 47–59.

Bennett CL, Christie J, Ramsdell F et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet. 2001; 27(1): 20–21.

Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a model of immune dysregulation. Curr Opin Allergy Clin Immunol. 2002; 2(6):481–487.

Ryba M. Myśliwska J. Biologia naturalnych limfocytów regultorowych CD4+CD25+. Postępy Biologii Komórki. 2006; 33(3):427–436.

Baecher-Allan C. Wolf E, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin. Immunol. 2004; 16:89–97.

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25 T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001; 193: 1285–1294

Budna J. Kaczmarek M. Sikora J. Znaczenie komórek T regulatorowych w rozwoju tolerancji na nowotwór. Postępy Biologii Komórki. 2011; 38 (2):283–295).

Śledź-Gawrońska B. Rola limfocytów T regulatorowych CD4+CD25+ w rozwoju zaburzeń o podłożu immunologicznym. Journal of Laboratory Diagnostic. 2010; 46(2):147–153.

Yang H, Qui L, Chen G. Proportional change of CD4+CD25+ regulatory T cells in decidua and peripheral blood in unexplained recurrent spontaneous abortion patients. Fertil Steril. 2008; 89:656–661.

Kukreja A, Cost G, Marker J, Zhang C, Sun Z, Lin-Su K, Ten S, Exley M, Wilson B, Porcelli S, Maclaren M. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest. 2002; 109: 131–140.

Brusko TM, Wasserfall CH, Clare-Salzlerm MJ, Schatz DA, Atkinson MA. Functional defects and the influence of age on the frequency of CD4+CD25+ T-cells in type 1 diabetes. Diabetes. 2005; 54: 1407–1414.

You S, Belghith M, Cobbold S, Alyanakian MA, Gouarin C, Barriot S, Garcia C, Waldmann H, Bach JF, Chatenoud L. Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. Diabetes. 2005; 54: 1415–1422.

Ehrenstein MR, Evan JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF-? therapy. J Exp. Med. 2004; 200: 277–285.

Viglietta V, Baecher. Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004; 199: 971–979.

Zou W. Regultory T cells, Tumour immunity and immunotherapy. Nat Rev Immunol. 2006, 6: 295–307.

Curiel TJ. Treg and rethinking cancer immunotherapy. J Clin Invest. 2007; 117: 1167–1174.

Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol. 2008 April; 20(2): 241–246.

Sato E, Olson SH, Ahn J, Budny B, Nishikawa H, Qian F. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005; 102: 18538–18543.

Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25: 267–296.

How to Cite
Frydrychowicz, M., Boruczkowski, M., Kolecka-Bednarczyk, A., Jenek, R., Rosołowska, J., Pluto-Prądzyńska, A., & Dworacki, G. (2016). Characteristics of Regulatory T cells. Journal of Medical Science, 85(4), 323.
Review Papers